首页 >> 研究进展
A clinical study on anti-HBV-DC-MTL in the HBeAg negative chronic hepatitis B virus infection
发布时间: 2013-09-02    人气指数:1065

ICI 2013---15th International Congress of Immunology

Poster Presentation (P6.11.77)

Frontiers Immunology (Electronic ISSN:1664-3224), doi: 10.3389/conf.fimmu.2013.02.00894.


Bang-FU Wu1, 2* and Jiang-Ying Yang2


  • 1 Southern Medical University Renkang Hospital, Gastroenterology and Hepatology Center, China
  • 2 Guangzhou Pubang Bio-Immunological Tech Research Institute, China

Aims: To observe the clinical efficacy of anti-HBV-DC-MTL, the dendritic cells(DC) and mixed T lymphocyte(MTL) originating from PBMC sensitized by HBsAg, in HBeAg negative chronic hepatitis B virus(HBV) infection.

Methods: 19 inactive HBsAg carriers and 19 chronic hepatitis B(CHB) patients were recruited in the study.PBMCs were obtained from 50ml peripheral blood. Anti-HBV-DC was proliferated from adherence PBMCs under the induction by GM-CSF and IL-4, and sensitized with 50µg HBsAg. Anti-HBV-MTL was proliferated from no-adherence PBMCs under the induction by IL-2, IL-12 and anti-HBV-DC. Anti-HBV-DC was harvested on day 7 and injected, half hypodermically and half intravenously, to patient once every two weeks for 12 times totally. Anti-HBV-MTL was harvested on day 14 and injected intravenously to patient once every two weeks for 12 times totally. Telbivudine was taken 600mg daily for 10 CHB patients those HBVDNA>10000 copy/ml. Quantitative HBVM(TRFIA) and HBVDNA were evaluated at week 0, 4, 12, and 24.
Results: Mean of HBsAg and HBVDNA decreased significantly at week 4, 12 and 24, HBsAg negative conversion rate were 10.53%(2/19), 15.79(3/19) and 21.05%(4/19) respectively, HBVDNA negative conversion rate were 69.23%(9/13), 76.92%(10/13) and 92.31%(12/13) in HBeAg negative CHB patients.
Mean of HBsAg decreased gradually along the time from week 4, 12 to 24,in inactive HBsAg carriers. At week 4, 12 and 24, HBsAg negative conversion rate were 15.79%(3/19), 26.32%(5/19) and 36.84%(7/19) respectively.

Conclusions: Anti-HBV-DC-MTL can effectively inhibit the viral replication, decrease rapidly and eliminate the HBsAg, and may eliminate the HBsAg for partial patients.


Keywords: Dendritic Cells (DC), Mixed T lymphocyte (MTL), Hepatitis B virus (HBV), Chronic hepatitis B (CHB), Inactive HBsAg carriers

Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.

Presentation Type: Abstract

Topic: Translational immunology and immune intervention

Citation: Wu B and Yang J (2013). A clinical study on anti-HBV-DC-MTL in the HBeAg negative chronic hepatitis B virus infection. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00894

Received: 20 Jun 2013; Published Online: 22 Aug 2013.

* Correspondence: Prof. Bang-FU Wu, Southern Medical University Renkang Hospital, Gastroenterology and Hepatology Center, Dongguan, Guangdong, 523952, China, bangfu.wu@163.com